Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$29.9 million.

  • Allogene Therapeutics' Free Cash Flow rose 32.97% to -$29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year increase of 27.05%. This contributed to the annual value of -$201.0 million for FY2024, which is 15.99% up from last year.
  • Allogene Therapeutics' Free Cash Flow amounted to -$29.9 million in Q3 2025, which was up 23.72% from -$39.1 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Free Cash Flow registered a high of -$29.9 million during Q3 2025, and its lowest value of -$70.1 million during Q1 2022.
  • Its 3-year average for Free Cash Flow is -$51.1 million, with a median of -$53.9 million in 2023.
  • Per our database at Business Quant, Allogene Therapeutics' Free Cash Flow slumped by 68.64% in 2021 and then skyrocketed by 38.44% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Free Cash Flow (Quarterly) stood at -$46.2 million in 2021, then tumbled by 38.15% to -$63.8 million in 2022, then grew by 15.52% to -$53.9 million in 2023, then soared by 31.42% to -$37.0 million in 2024, then soared by 32.97% to -$29.9 million in 2025.
  • Its last three reported values are -$29.9 million in Q3 2025, -$39.1 million for Q2 2025, and -$53.0 million during Q1 2025.